RxDoctor Payments Data

Gregory Knutzen, NP

Acute Care · Colton, CANPI 1871554170

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $33,588 of the $41,322 with a category attached, or 81.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,322in general payments, 2019–2025

Across 1,520 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sobi, Inc$5K
  • AstraZeneca$3K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Johnson & Johnson$2K
  • Novartis$2K
  • Merck$2K
  • plus $25K from 54 others

What the payments were for

  • Consulting fees$1,0653%
  • Speaking & faculty fees$3,0547%
  • Travel & lodging$1,4894%
  • Food & beverage$33,58881%
  • Education$2,1265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sobi, Inc33$4,789
AstraZeneca(2 entities)99$2,649
E.r. Squibb & Sons, L.L.C.136$2,567
Johnson & Johnson(2 entities)83$2,326
Novartis117$2,041
Merck77$1,920
Pfizer89$1,766
GSK26$1,680
Sanofi54$1,395
Bristol Myers Squibb62$1,389
Astellas Pharma US Inc46$1,240
Incyte Corporation39$1,197
Gilead(2 entities)47$1,109
Genentech USA, Inc.78$1,066
Amgen44$886
Eisai Inc.37$854
Lilly USA, LLC43$844
AVEO Pharmaceuticals, Inc.26$802
Seagen Inc.23$769
Regeneron Healthcare Solutions, Inc.20$680
TG Therapeutics, Inc.2$587
Pharmacyclics LLC, An Abbvie Company24$572
Daiichi Sankyo Inc.10$564
AbbVie14$537
Bayer23$526
Array Biopharma Inc26$512
Karyopharm Therapeutics Inc.14$480
Puma Biotechnology, Inc.16$397
Boehringer Ingelheim17$368
Takeda Pharmaceuticals U.S.A., Inc.9$364
Sumitomo Pharma America, Inc.23$351
Dendreon Pharmaceuticals LLC14$318
EMD Serono, Inc.16$313
Exelixis Inc.11$277
Myovant Sciences Inc.16$274
Pharmaessentia USA Corporation7$256
Ipsen Biopharmaceuticals, Inc11$224
ADC Therapeutics America, Inc.9$209
Sanofi-aventis U.S. LLC2$198
Caris MPI, Inc.6$179
Jazz Pharmaceuticals Inc.2$172
Taiho Oncology, Inc.8$167
Servier Pharmaceuticals LLC4$142
Dova Pharmaceuticals7$132
Global Blood Therapeutics, Inc.8$129
CTI Biopharma Corp.1$107
Mylan Institutional Inc.4$106
Mirati Therapeutics, Inc.4$103
Secura Bio, Inc.3$95
Rigel Pharmaceuticals, Inc.4$94
Tempus AI, Inc4$93
Agios Pharmaceuticals, Inc.4$92
Legend Biotech USA Inc.3$85
Iovance Biotherapeutics, Inc.2$57
Menarini Silicon Biosystems, Inc.2$50
Springworks Therapeutics, Inc.2$48
Emmaus Medical, Inc.3$46
Immunocore Limited1$29
Blueprint Medicines Corporation1$27
Adaptive Biotechnologies Corporation1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,322 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$21,143
Medicare patients
93
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate47$757,957
RevlimidLenalidomide12$275,297
SprycelDasatinib14$232,806
JakafiRuxolitinib Phosphate13$224,238
ErleadaApalutamide12$170,447
PromactaEltrombopag Olamine13$96,939
Everolimus17$29,396
Abiraterone Acetate13$28,284
Exemestane11$3,425
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen70$1,531
Anastrozole72$964
Morphine Sulfate ErMorphine Sulfate18$366
Hydroxyurea18$282
Letrozole15$241
Alendronate Sodium11$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali, Promacta$2,041$854,89560 claims
Bristol Myers SquibbRevlimid$1,389$275,29712 claims
E.r. Squibb & Sons, L.L.C.Sprycel$2,567$232,80614 claims
Incyte CorporationJakafi$1,197$224,23813 claims
Johnson & JohnsonErleada$2,326$170,44712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.

Other acute care in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →